Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

The development of in vitro mutagenicity testing systems using T-lymphocytes: Research progress report: June 1, 1988--May 31, 1989

Technical Report ·
DOI:https://doi.org/10.2172/6098183· OSTI ID:6098183
We will summarize our refinement of the methodology for cloning human T-lymphocytes and quantifying in vivo T-cell mutant frequencies at the hprt locus. The ability to maintain in vitro proliferation of these cells allows molecular characterizations, including analyses of hprt outlined elsewhere, the latter permits definitions of mutation frequencies which underlie the measured mutant frequencies. This unique aspect of the T-lymphocyte cloning assay is extremely important because it permits quantitation of in vivo mutational events, which are the events of public health interest. An increase in in vivo mutational events is only one of the causes of increased mutant frequencies, the other is in vivo clonal expansions of mutant cells. Clonal expansions have an importance of their own, but the implications are different than for increases in mutations. Several examples of in vivo clonal expansions will de detailed. The ability to maintain in vitro proliferation of T-cell colonies also allows molecular analyses of the mutations in the hprt gene. The results of both southern blot analyses for gene deletions and rearrangements and direct sequencing for smaller changes such as base substitutions will be given. A spectrum of hprt mutations is being developed both for unexposed, ''normal'' humans as well as for humans exposed to ionizing irradiation in the course of radioimmunoglobulin therapy (RIT) for hepatoma treatment. 11 figs., 4 tabs.
Research Organization:
Vermont Univ., Burlington (USA)
DOE Contract Number:
FG02-87ER60502
OSTI ID:
6098183
Report Number(s):
DOE/ER/60502-03; ON: DE89013800
Country of Publication:
United States
Language:
English